ADXS on NASDAQ

Advaxis

Logo: Advaxis, Public domain, via Wikimedia Commons4

American Pharmaceutical Company

Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm).3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

2002Founded1

Compare with TRAFALGAR INTERNATIONAL, INC., PRF Technologies Ltd. or BIOADAPTIVES, INC., or pick any stock.

  • TickerADXS on NASDAQ1
  • Industrybiotechnology1
  • HeadquartersPrinceton1
  • Websitewww.advaxis.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address9 Deer Park Drive, Suite K-1, Monmouth Junction, Nj 088525
  • Filer categoryNon-accelerated filer, Smaller reporting company5

See how the biggest companies compare on our leaderboards

Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-278969.2%Operating margin6
-369784.6%Net margin6
-98.1%Revenue growth, 20236

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue0¢$13.0K
  • Research and development86¢$24.1M
  • Income tax14¢$3.9M

Out of $13.0K in revenue.6 The company lost money this year.

Financial statements

Revenue78910116$13.0K in 2023−100% since 2017
0$10.0M$20.0M$30.0M2017: $12.0M$12.0M20172018: $6.1M$6.1M2018−50%2019: $20.9M$20.9M2019+244%2020: $253.0K$253.0K2020−99%2021: $3.2M$3.2M2021+1181%2022: $692.0K$692.0K2022−79%2023: $13.0K$13.0K2023−98%
Operating income78910116-$36.3M in 2023−63% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$98.4M-$98.4M20172018: -$70.4M-$70.4M2018−29%2019: -$18.0M-$18.0M2019−74%2020: -$26.4M-$26.4M2020+47%2021: -$18.8M-$18.8M2021−29%2022: -$37.5M-$37.5M2022+100%2023: -$36.3M-$36.3M2023−3%
Net income78910116-$48.1M in 2023−49% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$93.4M-$93.4M20172018: -$66.5M-$66.5M2018−29%2019: -$16.6M-$16.6M2019−75%2020: -$26.5M-$26.5M2020+59%2021: -$17.9M-$17.9M2021−33%2022: -$38.0M-$38.0M2022+113%2023: -$48.1M-$48.1M2023+26%
Fiscal year2017201820192020202120222023
Revenue$12.0M7$6.1M8$20.9M9$253.0K10$3.2M11$692.0K6$13.0K6
Cost of revenue$602.0K6$13.0K6
Gross profit$90.0K6
Research and development$70.5M7$57.0M8$26.7M9$15.6M10$10.6M11$27.9M6$24.1M6
Operating income-$98.4M7-$70.4M8-$18.0M9-$26.4M10-$18.8M11-$37.5M6-$36.3M6
Interest
Income tax-$4.4M7$50.0K8$50.0K9$50.0K10$50.0K11$584.0K6-$3.9M6
Net income-$93.4M7-$66.5M8-$16.6M9-$26.5M10-$17.9M11-$38.0M6-$48.1M6
Earnings per share-$11.0711-$13.136-$7.996
Earnings per share (diluted)-$13.136-$7.996

Compare Advaxis with another company

How it started

Beginnings

Advaxis was a Delaware corporation when it was acquired by a shell corporation in November 2004. The acquiring company was Great Expectations, which was incorporated in Colorado in June 1987. The only operating company owned by Great Expectations was Advaxis. In December 2004, a month after the acquisition, Great Expectations changed its name to Advaxis, and 18 months later it reincorporated as a Delaware corporation. The company's official 'date of inception' is 1 March 2002.

Partnerships

In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer.,

From Wikipedia’s article on Advaxis, shared under CC BY-SA 4.0.3

Former names

  • Advaxis, Inc.Jan 6, 2005 to Jan 13, 20235
  • GREAT EXPECTATIONS & ASSOCIATES INCDec 14, 1999 to Jan 5, 20055

Timeline

  1. 2002Founded Founded1

Recent filings

  1. Apr 26, 202410-K/A
  2. Apr 19, 20248-K/A
  3. Apr 16, 202410-K
  4. Apr 3, 20248-K
  5. Mar 29, 20248-K
  6. Mar 6, 20244
  7. Mar 5, 20248-K
  8. Feb 23, 20248-K
  9. Feb 12, 20244
  10. Feb 9, 20248-K
  11. Feb 6, 20248-K
  12. Jan 3, 20248-K/A
  13. Nov 21, 20234
  14. Nov 20, 202310-Q
  15. Nov 8, 20233

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15